TM-Flow System and Diabetic Neuropathy: Objective Testing for Symptomatic and At-Risk Patients

Objective Diabetic Neuropathy Testing with the TM-Flow System

Diabetic neuropathy affects up to 50 percent of long-term diabetes patients and often begins with subtle nerve damage before overt symptoms appear. Small-fiber neuropathy—affecting pain and temperature fibers—is particularly difficult to characterize with traditional methods. The TM-Flow System offers a non-invasive, objective way to measure autonomic and sensory function in symptomatic and at-risk diabetic patients, giving clinicians measurable data to act on.

As with any diagnostic device, neuropathy testing protocols should account for device contraindications and proper use — see the product safety information for the FDA-cleared TM-Flow System.

A thorough diabetic foot exam remains the front line for identifying these complications.

Understanding Diabetic Neuropathy

Chronic hyperglycemia leads to oxidative stress, microvascular ischemia and metabolic damage to nerve fibers. Small fibers are often affected first, causing burning, tingling, or sweating abnormalities. By the time nerve-conduction studies show abnormality, significant damage has occurred. Objective testing supports glycemic optimization and neuroprotective interventions.

The Challenge of Small-Fiber Assessment

Traditional tests like monofilament and tuning fork are subjective and detect only late stages. Nerve conduction studies evaluate large fibers and miss small-fiber neuropathy. This creates a diagnostic gap in diabetic care—precisely where the TM-Flow System adds value. It quantifies sudomotor function (sweat gland response), HRV, and vascular indices in a single 7 to 10 minute procedure.

TM-Flow System Overview for Diabetes Care

• Sudomotor Testing: The SweatC module measures skin conductance changes to assess autonomic small-fiber function. Low conductance indicates neuropathy.
• HRV Analysis: Assesses autonomic balance—reduced HRV signals autonomic dysfunction common in diabetes. (TMFlowSystem.com)
• ABI Measurement: Assesses for PAD, a common complication in diabetes, with automated accuracy.
• Together, these parameters offer a multi-system snapshot of neurological and vascular health.

Integrating TM-Flow in Diabetes Clinics

Endocrinologists can include the TM-Flow test in the annual diabetic neuropathy evaluation the ADA recommends, or as part of the comprehensive metabolic assessment. Workflow: patient registration → vitals → TM-Flow test → results → physician discussion. Each session takes 7 to 10 minutes and is handled by trained assistants.

Benefits for Clinicians and Patients

• Quantifies small-fiber function objectively
• Improves coding and documentation for reimbursement
• Engages patients in their care plan
• Enhances outcomes and reduces amputation risk

FAQs

1. Is the test pain-free? Yes, completely non-invasive.
2. Can I use it for type 1 and type 2 diabetes? Yes.
3. How often should patients be tested? Annually for stable, semi-annually for high risk.
4. Is the test covered by Medicare? It is addressed under Medicare Local Coverage Determinations when medical necessity is documented. Confirm coverage with your Medicare Administrative Contractor’s LCD.
5. Does it replace NCS? No, it complements it.

Conclusion

For diabetes clinics, the TM-Flow System bridges a critical gap in small-fiber and autonomic assessment, offering objective, quantifiable data to guide proactive care and reduce complications.

Ready to get started? Learn how HealthWright Advantage bundles the device, training, and ongoing support your practice needs — backed by our 60-day buyback: bill the CMAT Advantage tests correctly and compliantly, and if Medicare does not reimburse them, we buy the system back.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and clinical decision-making.

Frequently Asked Questions

How does the TM-Flow System support diabetic neuropathy evaluation?

The TM-Flow System measures sudomotor (sweat-gland) function and heart-rate variability, which can reflect small-fiber and autonomic nerve changes that other methods may miss. These are objective measurements used to support a physician’s clinical assessment, not a stand-alone diagnosis.

Is the testing invasive or painful for diabetic patients?

No. The measurements are non-invasive and are typically completed in a single short office visit.

Which CPT codes are associated with the measurements?

The measurements correspond to established codes such as sudomotor function (CPT 95923) and heart-rate variability (CPT 95921). Code selection, documentation, and coverage are the responsibility of the billing provider and should be verified against current payer policy.

Does the TM-Flow System replace nerve conduction studies?

No. It complements other evaluations. The CMAT Advantage System provides autonomic and small-fiber measurements that can prompt earlier follow-up, while nerve conduction studies assess large-fiber function.

CPT codes are provided for informational purposes only and do not guarantee reimbursement. Verify code applicability and coverage with the relevant payer and your billing department before submitting claims. CPT® is a registered trademark of the American Medical Association.